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Abstract
Background: The relapse of cancer after radiotherapy is a clinical knotty problem. Previous
studies have demonstrated that the elevation of several factors is likely in some way to lead to the
development of treatment tolerance, so it is necessary to further explore the problem of re-
proliferated radioresistant cells to chemotherapeutic agents. In the present study, we aimed to
investigate the chemosensitivity of radioresistant cells originated from the multicellular spheroids
of A549 lung adenocarcinoma.
Methods: After irradiated with 25 Gy of 6 MV X-ray to A549 multicellular spheroids, whose 10th
re-proliferated generations were employed as radioresistant cells, and the control groups were
A549 parental cells and MCF7/VCR resistant cells. The chemo-sensitivity test was made by six kinds
of chemotherapeutic drugs which were DDP, VDS, 5-Fu, HCP, MMC and ADM respectively, while
verapamil (VPL) was used as the reversal agent. Then the treatment effect was evaluated by MTT
assay, and the multidrug resistant gene expressions of mdr1 and MRP were measured by RT-PCR.
Results: Both A549 parental cells and A549 derived radioresistant cells were resistant to DDP,
but sensitive to VDS, 5-Fu, HCP, MMC and ADM. The inhibitory rates of VPL to these two types
of cell were 98% and 25% respectively (P < 0.001). In addition, without drugs added, the absorbance
value (A value) of A549 parental cells was 2-folds higher than that of their radioresistant cells (P <
0.001). As to the MCF7/VCR cells, they were resistant to DDP and VDS, but slight sensitive to
MMC, ADM, 5-Fu, and HCP with 80% of inhibitory rate to VPL. The subsequent RT-PCR
demonstrated that the Mdr1/β2-MG and MRP/β2-MG of all A549 cells were about 0 and 0.7
respectively, and those of MCF7/VCR cells were 35 and 4.36.
Conclusion: The chemosensitivity of A549 radioresistant cells had not changed markedly, and the
decreased sensitivity to VPL could not be explained by the gene expression of mdr1 and MRP. It is
possible that the changes in the cell membrane and decreased proliferate ability might be attributed
to the resistance. Unlike multidrug resistance induced by chemotherapy, VPL may be not an ideal
reverser to radioresistant cells. Therefore, the new biological strategy needs to be developed to
treat recurring radioresistant tumor in combination with chemotherapy.
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Backgrounds
In patients with breast cancer, 4–47% may have local
tumor relapse after chemotherapy and ionizing radiation
therapy, this may be related to the sub-clinical focuses and
resistant cell population, indicating bad prognosis [1].
Because the radiation dose may be lethal in case of relapse
of the cancer after radiotherapy, a second time of radia-
tion therapy would not be favored but chemotherapy
would be an alternative in such cases. Therefore, it is nec-
essary to explore the problem of re-proliferated radiore-
sistant cells to chemotherapeutic agents [2].
Multicellular spheroid (MTS) is a three-dimensional
structure formed by cancer cells, which could be used for
radio-biological study and bioassay on drug sensitivity in
vitro. The results obtained from this assay are closely
mimic in vivo setting [3,4]. The microenvironment and
cell cycle between A549 lung adenocarcinoma MTS and
single layers are different [5]. Our former article had
shown that the cell cycle retardation during G2-M phase
became increased with increase of the irradiation dose,
and only a few cells survived, proliferated and relapsed
after prolonged subculture. The growth of radioresistant
descendant cells was slow with low sensitivity to radiation
[6]. Whether the change of drug sensitivity to chemother-
apeutic agent in re-proliferated radioresistant cells may
result in reduction and resistant, or sensitive, or the same
as the primary cells is a problem worth to further investi-
gate. In general, the mechanism of radioresistance and
chemotherapy tolerance may have a common basis, and
tumor cells at different cell cycle phase may have different
degree of sensitivity to radiation and chemotherapeutic
agents. For instance, cells in proliferate stage may be more
sensitive. The survival of a few polyploidy giant cells in
tumor after irradiation is perhaps due to p53 gene muta-
tion resulting from DNA damage. The repairmen of tumor
cells and tolerance to DNA damage form the basis of tol-
erance in the survived re-proliferated cells [7]. Radiation
can also influence the apoptosis and some gene expres-
sion in regulating the cell cycle, e.g. C-Jun NH2-terminal
kinase (JNK), protein kinase C (PKC), nerve ceramide cas-
cade protein [8], survivin (an inhibition substance of
membranous structure in the apoptosis protein family)
[9] and CD40 activating signal [10], etc. The elevation of
the above factors is likely in some way to lead to the devel-
opment of tolerance.
In this study, MTS formed by A549 lung adenocarcinoma
cells was used as the experimental model to assess chem-
osensitivity of radioresistant cells. A549 MTS was first
treated with irradiation of 6 MV X-ray, then the suscepti-
bility of radioresistant regrowth cells to chemotherapeutic
agents and their multidrug resistance gene expression
were analyzed thereafter.
Methods
Culture and irradiation of A549 MTS
6MV X-ray was used for single irradiation to A549 MTS,
with irradiation dosage 15, 20, 25 and 30 Gy respectively
and dosage rate 200 cGy/min. Then the MTS was cultured
according to the conventional MTS culture methods [3,6],
and the culture liquid was changed weekly. Living re-pro-
liferated cells were noted 40 days after irradiation of 25 Gy
or 30 Gy [6], with the radioresistant cells being the 10th
generation cell after 25 Gy irradiation. Other irradiation
groups were mainly 15 Gy 32P internal irradiation and
6MV X-ray external irradiation [11].
Six kinds of chemotherapeutic drugs and verapamil in 
culture solution
The six kinds of chemotherapeutic agents were Cisdiami-
nodichloro-platinum (DDP), vindesin (VDS), 5-Fluorou-
racil (5-Fu), Hydroxycamptothecine (HCP), Mitomycin C
(MMC), and Adriamycin (ADM), being cell cycle nonspe-
cific agents, e.g. alkylating agents and anti-tumor antibiot-
ics, and cell cycle specific agents, e.g. antimetabolites. The
6 kinds of chemotherapeutic agents were prepared respec-
tively with 1640 culture solution to form 2-folds of peak
plasma concentration (2× PPC) for use. When the solu-
tion was used for assay, added 100 μl culture solution
which containing equal amount of cells with another 100
μl of the above stock solution, so the concentration of the
chemotherapeutic agent was reduced by half, i.e. equal to
1× PPC which were DDP 10.0 mg/L, VDS 1.0 mg/L, 5-Fu
110 mg/L, HCP 5.0 mg/L, MMC 3.0 mg/L, and ADM 10.0
mg/L. Taking 0.2 mg/ml (200 mg/L) verapamil (VPL)
(Shanghai Hefeng Pharmaceutical Co. Ltd. China. Vera-
pamil hydrochloride Injection, 5 mg/2 ml) which was
equal to 200 folds of the known 1× PPC (0.1 to 1.0 mg/
L)[12], added VPL to A549 parental cells, A549 radiore-
sistant cells, and MCF-7 vincristin resistant (MCF7/VCR)
cells respectively without chemotherapeutic agents added
for the observation of VPL on cell toxicity. Another group
was the combined treatment of VPL and chemotherapeu-
tic agent for MCF7/VCR cells.
Drug sensitiveness experiment of monolayer cell
One 96 well cell culture plate was used, with each group
containing 4 wells and the experiment group having
20000 cells per well. The blank well had no cells added,
but added with 200 μl culture solution. In the control
group, 100 μl culture solution contained cells and another
100 μl culture solution without cell added. As to the ADM
blank control group, 100 μl drug containing solution and
100 μl culture solution were added respectively.
MTT assay methods
Testing cells added with chemotherapeutic drug were cul-
tured for 48 hrs, and then added with 20 μl MTT (5 mg/
ml) to every well. After 4 hrs the A value at 490 nm wasJournal of Experimental & Clinical Cancer Research 2009, 28:72 http://www.jeccr.com/content/28/1/72
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measured with DG-3022A model enzyme-linked immu-
nosorbent assay instrument (produced by Huadong Elec-
tronic Tube Factory, China) and the sensitivity experiment
was performed.
Evaluation of the therapeutic efficacy in MTT experiment
Taking the 1× PPC for the standard in the drug sensitivity
experiment, cell survival rate = (A value in the experimen-
tal group/A value in the control group) × 100%, and inhi-
bition rate = 1 – cell survival rate. Standard for the
evaluation of drug sensitivity was as followed, i.e. Sensi-
tive: 100% > inhibition rate % > 70%; Relatively Sensitive:
70% > inhibition rate % > 20%; Insensitive: 20% > inhi-
bition rate %> 0%.
Use RT-PCR methods for the evaluation of mdrl and MRP
multi-drug resistant gene expression in A549 parent cells,
A549 radioresistant cells and MCF7/VCR resistant
cells[13,14].
Results
Drug sensitivity tests of A549 parent cells and A549 
radioresistant cells
At the beginning of the culture, the number of initial cells
was the same between the two groups. Two days after
being cultured under the same condition without drug
added, the A value of parent cells in the control group was
2 times higher than that of the radioresistant cell group,
and their A values were 0.635 ± 0.044 and 0.293 ± 0.013
respectively (P < 0.001). It is found that A549 parent cells
and A549 radioresistant cells were DDP resistant, but sen-
sitive to VDS, 5-FU, HCP, MMC and ADM, therefore the
sensitivity of A549 radioresistant cells to chemotherapeu-
tic drug was about the same as that of their parent cells
(Table 1). When treated with VPL but without chemother-
apeutic drug added, A549 parent cells had strong toxicity
effects with A value 0.017 ± 0.018, but their radioresistant
cells had weak toxicity effects with an A value of 0.235 ±
0.026 (P < 0.001), as a result of 98% and 25% inhibition
rate to these two cells respectively (Table 1).
Drug sensitivity experiment on MCF7/VCR cells
MCF7/VCR cells were resistant to DDP and VDS, but were
relatively sensitive to MMC, ADM, 5-FU, and HCP. MCF7/
VCR cells added with VPL but without chemotherapeutic
drug had strong toxicity effects, with an A value of 0.10 ±
0.028 and an inhibition rate of 80% (table 1).
After combined treatment of VPL and chemotherapeutic
agents for MCF-7/VCR cells, the relatively sensitivity drugs
became sensitive and inhibitive rate of resistant DDP
increased 50%, but resistant drug VDS was not reversed (P
= 1.00) (table 1).
Mdr1 and MRP multi-drug resistant gene expression
Using RT-PCR method, mdr1 and MRP multi-drug resist-
ant gene expressions were assessed in A549 parent cells,
A549 radioresistant MTS, re-proliferated cells after irradi-
ation to A549 MTS, and MCF7/VCR resistant cells, while
β2-MG serves as the internal reference (Table 2). The
results showed that the Mdr1/β2-MG in all A549 cells
were 0, and the MRP/β2-MG gene expressions ranged
from 0.3 to 0.7 in all those cells showing variable degrees
of reduction after irradiation, but the values of Mdr1/β2-
MG and MRP/β2-MG in MCF7/VCR resistant cells were 35
and 4.36 respectively.
Discussion
In this study, re-proliferated cells derived from post-irradi-
ated A549 lung adenocarcinoma MTS were used for an
investigation of the disparity of drug sensitivity between
the radioresistant cells and their parent cells. It is of great
significance for the rational option of chemotherapeutic
programs for relapsed cancer after radiotherapy.
The living cell number of A549 MTS became decreased
after a medium dose of irradiation, and their mdrl and
MRP gene expression levels examined by RT-PCR became
temporarily reduced, subsequently showed little variation
with their parent cells after re-proliferated. In mono-layer
culture, A549 re-proliferated radioresistant cell was resist-
ant to DDP, but sensitive to VDS, 5-Fu, HCP, MMC and
ADM. The sensitivity to the 6 kinds of chemotherapeutic
Table 1: Drug sensitivity tests on A549 parent cells, radioresistant cells and MCF7/VCR resistant cells
No. Drug A549 parent cells A549 radioresistant cells MCF7/VCR resistant cells Combine VPL and chemotherapeutic agent for MCF-7 
cells
1 DDP 7 Insensitive 0 Insensitive 0 Insensitive 50 Relatively sensitive
2 MMC 93 Sensitive 100 Sensitive 58 Relatively sensitive 83 Sensitive
3 VDS 72 Sensitive 38 Relatively sensitive 0 Insensitive 0 Insensitive
4 ADM 79 Sensitive 97 Sensitive 31 Relatively sensitive 92 Sensitive
5 5-FU 90 Sensitive 100 Sensitive 68 Relatively sensitive 75 Sensitive
6 HCP 91 Sensitive 94 Sensitive 60 Relatively sensitive 83 Sensitive
7 VPL 98 Sensitive 25 Relatively sensitive 80% Sensitive -
Note: The digit in the results is inhibition rate %, the writing is the explanation of the sensitivity.Journal of Experimental & Clinical Cancer Research 2009, 28:72 http://www.jeccr.com/content/28/1/72
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drugs between the radioresistant cells and their parent
cells were almost the same, but the radioresistant cells was
resistant to high concentration of VPL, however their par-
ent cells were sensitive to it. The mdrl and MRP multi-drug
resistant gene expression in MCF7/VCR cells showed a
very high level. Moreover, the cells which were resistant or
had low sensitivity to a variety of chemotherapeutic
agents showed a higher sensitivity to high concentration
of VPL than A549 re-proliferated radioresistant cells. VPL
had not significant cell toxicity in a concentration of 10
μg/ml. It was found that a high concentration of VPL was
needed for the in vitro reversion experiment of drug-resist-
ance. In this article, the concentration of 200× PPC of VPL
was used for in vitro experiment. If intra-arterial infusion
or chemotherapeutic embolism were used for solid
tumor, such a high local concentration can be achieved in
the tumor without affecting the general dose and PPC in
the body. According to comparative analysis, the reduc-
tion of sensitivity of A549 re-proliferated radioresistant
cells to VPL was not due to the levels of mdrl and MRP
multidrug resistant genes. It has been reported in litera-
ture that the over-expression of GSH transferase (GST) pi
protein in the MCF-7 cells after irradiation leads to an
increase of VCR-resistance by 5-times, and the resistance
to VP-16 increased by 3-times. In MCF-7 drug resistant
sub-line, the selective resistance to some drugs may be
related to an increase of the intracellular GST activity [15].
It is generally accepted that the MRP drug resistance is
indirectly mediated through transporting a compound
formed by GS-X and chemotherapeutic agents within the
cells. In this article, the MRP-resistant gene expression
level of A549 re-proliferated radioresistant cell showed no
evident elevation, and the parent cells and radioresistant
cells were resistant to DDP, which may be due to the
increase of GST within the cells [14]. Whether the reduc-
tion of VPL sensitivity related to this condition is worthy
of further investigation.
VPL is a Ca2+ blocking agent inhibiting the elevation of
intracellular calcium and reducing cell death. When the
cellular concentration of VPL is high, the drug sensitivity
is elevated and consequently the cell death is enhanced.
When the inflow of VPL to the radioresistant cells is
decreased or the excretion is increased, the drug sensitivity
is decreased. Whether the reduced sensitivity of radiore-
sistant cells to VPL is attributable to the formation of pro-
tection protein on the surface of the membranous
structure awaits further investigations. Apoptosis is
involved in Ca2+ flowing into the cytoplasm from endo-
plasmic reticulum, which can be inhibited by BCL-2. The
BCL-2 protein expression is increased in the radioresistant
cells [16,17]. Whether the reduction of VPL toxicity is
related to the increase of BCL-2 protein is unknown. The
pharmacological target of chemotherapeutic drug is DNA,
but VPL affects the cell membrane and the calcium pas-
sage. It is postulated that, after repairing DNA damage
induced by irradiation in A549 pulmonary adenocarci-
noma MTS, some changes in membrane proteins may
occur. In addition, the MTT test showed that the A value
of A549 parent cells was two times higher than their radi-
oresistant cells, which illustrated that the re-proliferate
ability of radioresistant cell may be reduced. As a result,
the excretion of VPL is increased, leading to the develop-
ment of VPL resistance. The detailed mechanism is cur-
rently unknown.
VPL is generally accepted as a drug resistant reversion
agent, but it seems that the radioresistance is different
from the multiple drug resistance induced by chemother-
apy, and that VPL is probably not an ideal reversion agent
for radioresistant cells. Therefore, new strategies need to
be developed for the management of the relapse of radi-
oresistant tumors in combination with chemotherapy.
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Table 2: Semi-quantitative analysis of mdr1 and MRP in A549 cells, A549 MTS after irradiation, and MCF7/VCR cells
Type of cells Mdr1/β2-MG MRP/β2-MG
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A549 MTS 0 0.62
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